IL4I1 and Peripheral demyelination: To determine if the therapeutic administration of IL4I1-derived AKAs affects inflammation and remyelination in vivo, LPC-induced demyelination was performed on mice, followed by treatment with a combination of 200 mg/kg PPA, 200 mg/kg IPA, and 200 mg/kg HPPA through daily oral gavage from 7 to 14 dpl during the period of oligodendrocyte differentiation.